Zipalertinib
Zipalertinib is an investigational new drug that is being evaluated for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations, particularly exon 20 insertion mutations.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Zipalertinib is an investigational new drug that is being evaluated for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations, particularly exon 20 insertion mutations.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1372273941 under CC BY-SA 4.0; modifications have been made.